Early ritonavir-lnduced maculopapular eruption

Dermatology

Volumn 195, Issue 3, 1997, Pages 301-302

  Bachmeyer, C ^a   Blum, L ^b   Cordier, F ^a   Launay, E ^c   Danne, O ^b   Aractingi, S ^d   Mougeot Martin, M ^a  

^a CENTRE HOSPITALIER LAENNEC   (France)

^b Service de Médecine et   (France)

^c CENTRE HOSPITALIER RENÉ DUBOS   (France)

^d HÔPITAL TENON   (France)

Author keywords

Adverse cutaneous reaction; HIV infection; Ritonavir

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PAPULAR SKIN DISEASE; PRIORITY JOURNAL; PROVOCATION TEST; RECURRENT DISEASE; REMISSION;

ADULT; ANTI-HIV AGENTS; DRUG ERUPTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RITONAVIR;

EID: 0030728885     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000245969     Document Type: Article

References (13)

1. Carr A. Swanson C. Penny R, Cooper DA: Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993;167:180-185.
2. Coopman SA. Johnson RA. Platt R. Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674.
3. Saiag P. Caumes E. Chosidow O. Revuz J, Roujeau JC: Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992:26:567-574.
4. Darner SA. Carr A. Leonard JM et al: A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of IIIV-1 protease. N Engl J Med 1995;333:1528-1533.
5. Markowitz M. Saag M. Powderly WG et al: A preliminary study of ritonavir, an inhibitor of HIV-1 protease to treat HIV-I infection. N Engl J Med 1995:333:1534-1539.
6. Carr A. Gross AS. Hoskins JM. Penny R. Cooper DA: Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sul-phamethoxazole in HIV-infected patients. AIDS 1994:8:333-337.
7. Carr A. Vella S. de Jong MD. Sorice F. Imrie A. Boucher CA. Cooper DA: A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenemic HIV-infected patients. AIDS 1996:10:635-641.
8. Carr A. Penny R, Cooper DA: Efficacy and safety of rechallenge with low-dose trimethoprim-sulfamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993:7: 65-71.
9. Carr A, Penny R. Cooper DA: Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol 1993;91:683-685.
10. Roujeau JC. Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994: 331:1272-1285.
11. Absar N. Daneshvar H. Beall G: Desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994;93:1001-1005.
12. Gluckstein D. Ruskin J: Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): Use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995:20:849-853.
13. Bachmeyer C, Salmon D. Guerin C. Barre C, Hazcbroueq G. Sicard D. Sereni D: Trimethoprim-sulfamethoxazole desensitization in HIV-infected patients: An open study. AIDS 1995:9:299-300.